AMENDMENT NO. 1 TO LICENSE AGREEMENT BY AND BETWEEN KARYOPHARM THERAPEUTICS INC. AND BERLIN-CHEMIE AGLicense Agreement • May 4th, 2023 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (the “Amendment”) is made and entered into as of May 19, 2022 (the “Amendment Effective Date”), by and between Karyopharm Therapeutics Inc., a corporation organized and existing under the law of Delaware and having its principal place of business at 85 Wells Ave., 2nd floor Newton, MA 02459 (“Karyopharm”) and Berlin-Chemie AG, a corporation organized and existing under the law of Germany and having its principal place of business at Glienicker Weg 125, 12489 Berlin, Germany(“Berlin-Chemie”).
AMENDMENT NO. 2 TO LICENSE AGREEMENT BY AND BETWEEN KARYOPHARM THERAPEUTICS INC. AND BERLIN-CHEMIE AGLicense Agreement • May 4th, 2023 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 (the “Amendment”) is made and entered into as of March 14, 2023 (the “Amendment Effective Date”), by and between Karyopharm Therapeutics Inc., a corporation organized and existing under the law of Delaware and having its principal place of business at 85 Wells Ave., 2nd floor Newton, MA 02459 (“Licensor”) and Berlin-Chemie AG, a corporation organized and existing under the law of Germany and having its principal place of business at Glienicker Weg 125, 12489 Berlin, Germany (“Licensee”). All capitalized terms used but not defined herein shall have the meanings set forth in the License Agreement (as defined herein).
